Vanderbilt University Medical Center

Stanford Medicine’s Research Participation services has developed the Participant Engagement Platform (PEP) as a way of offering and managing “honest broker” outreach, such as Direct Email and Epic MyChart. The Research Participation team (honest broker) sends the study invitation to potential participants (identified via EHR cohort search) on behalf of the study team. Only when a potential

This presentation will help answer the question “Should you go online” and other things to consider when deciding if social media will be an option to add to your recruitment plan.

By the end of this presentation, viewers will be able to: 1. Define team science and differentiate team science research from more traditional forms 2. Identify how team science is promoted by the NIH 3. Explain the benefits and shortcomings of teams science research 4. Describe the risks associated with team science models and how to overcome them 5. Describe real-world examples of how team

Clinical research must be modernized. There are increasing demands to have more rapid innovation in order to develop novel treatments more quickly and cost effectively. The challenges that COVID add to the landscape of clinical trials also brings potential for new pathways of clinical trial innovation. Join this discussion to hear about the potential factors driving the decision to use an

We will provide an overview of the project aims and progress so far in building this collaborative set of tools to collect, analyze, share and act on participant feedback. We will describe how the project integrates with into local participant-centered initiatives at collaborating sites.

This webinar will provide an overview of the STELLAR prototype– an interactive web-based system to assess the learning needs of the clinical and translational research workforce, a Self-career Training, Education, Life-long Learning Advancement Resource.

Researchers planning COVID-19 trials with the Trial Innovation Network (TIN) can leverage the N3C to inform their research hypotheses. N3C focuses on aligning its infrastructure so that it can generate efficient and minimally biased results. Part of that infrastructure includes the curation of value sets and phenotype variables relevant to COVID-19, such as ventilator support, ICU use, and

Learn more about obtaining patient-center feedback from underrepresented groups to enhance your research project even in the times of COVID. The CES Team will highlight it’s transition to the use of Zoom technology, how to address issues of tech-equity and literacy, and share lessons learned for effectively facilitating group dialogue in a virtual forum.

This webinar presents scholarly research conducted by the Tufts Center for the Study of Drug Development, Tufts University School of Medicine examining trends in protocol design practice and their impact on clinical trial performance and quality. In particular, the webinar will explore innovative approaches being used to leverage patient and study volunteer input and experience to modify protocol

Implementing your research project within an Electronic Health Record (EHR) system is an exciting but complex endeavor that requires specialized tools and approaches. This talk will unpack what dedicated teams of informaticians have pioneered over the past decade. It will help the researcher understand a path forward for their research protocols. The talk addresses key differences between

The NIA staff will discuss some of the limitations with inclusion of diverse populations observed in clinical research and trials, the role federal science policy is playing in remedying the limitations and promoting more broad and consistent inclusion of communities of color in developing new strategies implemented to enhance inclusion among older persons of color. The NIA team will provide an

This webinar will provide an updated overview of Trials Today – an online tool that helps potential participants find studies that are of interest to them and their health condition. Trials Today is a quick and easy way to search the thousands of studies in ClinicalTrials.gov that are recruiting participants.

A collaborative research model was developed and tested to enable regional healthcare systems to join multisite clinical trials emanating from the Clinical and Translational Science Award(CTSA) Trial Innovation Network (TIN) by the Institute of Translational Health Sciences at the University of Washington and the Northwest Participant and Clinical Interactions(NW PCI) Network. The NW PCI is a

Researchers are increasingly using Facebook to recruit prospective participants in research studies. Due to the limited guidelines and regulations regarding the use of social media, institutions and sponsors struggle with the timely and effective evaluation of social media protocols. To harness the potential of social media and to ethically and effectively recruit participants into research

The All of Us Research Program aims to accelerate health research and medical breakthroughs, enabling individualized prevention, treatment, and care by providing researchers access to one of the largest biomedical datasets of its kind. During this session, we will introduce you to the All of Us Researcher Workbench and show how researchers use this platform to access and analyze All of Us data. We

What we have learned to optimize recruitment messaging, REDCap survey options, and strategies when using ResearchMatch will be discussed.

Recruitment goals and timelines is a consistent challenge. This session will provide practical guidance and tips to develop effective recruitment plans, track and measure success, and create eye-catching recruitment materials.

Unlike other tools designed for IT professionals, Criteria2Query is an open source software to be used directly by clinical research coordinators or clinical trial designers to facilitate study feasibility analysis and cohort identification. Coordinators can input clinical trial eligibility criteria in English, which will be coded and used to formulate cohort queries automatically. Coordinators

I will overview methods for validation of surrogate endpoints, and apply these methods for clinical trials of chronic kidney disease. I’ll then show how models that relate treatment effects on clinical endpoints to treatment effects on surrogate endpoints based on past clinical trials can be applied to improve the design and interpretation of newly conducted clinical trials which measure surrogate